Assignee
PROQR THERAPEUTICS II BV
NL·25 granted patents·22 pending applications·92 citations·filing 2013–2025
Top patents by PatentIndex Score
47 records- 0193US11851656B2Chemically modified single-stranded RNA-editing oligonucleotidesPROQR THERAPEUTICS II BV·Filed 2021·Granted Dec 26, 2023·6 cites·40 claims
- 0293US10941402B2Chemically modified single-stranded RNA-editing oligonucleotidesPROQR THERAPEUTICS II BV·Filed 2017·Granted Mar 9, 2021·16 cites·22 claims
- 0393US10676737B2Targeted RNA editingPROQR THERAPEUTICS II BV·Filed 2015·Granted Jun 9, 2020·12 cites·31 claims
- 0492US11781134B2Targeted RNA editingPROQR THERAPEUTICS II BV·Filed 2020·Granted Oct 10, 2023·3 cites·19 claims
- 0591US12203072B2Chemically modified single-stranded rna-editing oligonucleotidesPROQR THERAPEUTICS II BV·Filed 2023·Granted Jan 21, 2025·1 cites·29 claims
- 0691US12018257B2Single-stranded RNA-editing oligonucleotidesPROQR THERAPEUTICS II BV·Filed 2023·Granted Jun 25, 2024·2 cites·13 claims
- 0791US11274300B2Oligonucleotide complexes for use in RNA editingPROQR THERAPEUTICS II BV·Filed 2018·Granted Mar 15, 2022·17 cites·20 claims
- 0890US11649454B2Single-stranded RNA-editing oligonucleotidesPROQR THERAPEUTICS II BV·Filed 2021·Granted May 16, 2023·4 cites·41 claims
- 0988US10988763B2Single-stranded RNA-editing oligonucleotidesPROQR THERAPEUTICS II BV·Filed 2017·Granted Apr 27, 2021·13 cites·20 claims
- 1085US2025223593A1Chemically modified single-stranded rna-editing oligonucleotidesPROQR THERAPEUTICS II BV·Filed 2024·Application pending·0 cites
- 1184US12545911B2Single-stranded RNA-editing oligonucleotidesPROQR THERAPEUTICS II BV·Filed 2024·Granted Feb 10, 2026·0 cites·12 claims
- 1284US10760076B2Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansionPROQR THERAPEUTICS II BV·Filed 2016·Granted Sep 1, 2020·2 cites·6 claims
- 1383US10617707B2Oligonucleotides to treat eye diseasePROQR THERAPEUTICS II BV·Filed 2017·Granted Apr 14, 2020·2 cites·15 claims
- 1482US12275937B2Stereospecific linkages in RNA editing oligonucleotidesPROQR THERAPEUTICS II BV·Filed 2019·Granted Apr 15, 2025·2 cites·14 claims
- 1582US10612025B2Antisense oligonucleotides for the treatment of eye diseasePROQR THERAPEUTICS II BV·Filed 2017·Granted Apr 7, 2020·2 cites·11 claims
- 1680US11123360B2Oligonucleotides to treat eye diseasePROQR THERAPEUTICS II BV·Filed 2020·Granted Sep 21, 2021·1 cites·17 claims
- 1778US2024141336A1Targeted rna editingPROQR THERAPEUTICS II BV·Filed 2023·Application pending·0 cites
- 1877US10889817B2Oligonucleotide therapy for Leber Congenital AmaurosisPROQR THERAPEUTICS II BV·Filed 2019·Granted Jan 12, 2021·1 cites·6 claims
- 1974US10421963B2Oligonucleotide therapy for leber congenital amaurosisPROQR THERAPEUTICS II BV·Filed 2016·Granted Sep 24, 2019·2 cites·14 claims
- 2070US10900041B2Antisense oligonucleotides for use in treating Alzheimer's diseasePROQR THERAPEUTICS II BV·Filed 2016·Granted Jan 26, 2021·3 cites·14 claims
- 2168US11920132B2Oligonucleotide therapy for Leber congenital amaurosisPROQR THERAPEUTICS II BV·Filed 2021·Granted Mar 5, 2024·0 cites·2 claims
- 2268US9994856B2Method for increasing the activity of a cystic fibrosis transmembrane conductance regulator proteinPROQR THERAPEUTICS II BV·Filed 2017·Granted Jun 12, 2018·1 cites·18 claims
- 2368US2021401871A1Oligonucleotides to treat eye diseasePROQR THERAPEUTICS II BV·Filed 2021·Application pending·0 cites
- 2468US2025333734A1Antisense oligonucleotides for the treatment of Stargardt diseasePROQR THERAPEUTICS II BV·Filed 2024·Application pending·0 cites
- 2565US2026027237A1Chemically modified oligonucleotides for adar-mediated rna editingPROQR THERAPEUTICS II BV·Filed 2023·Application pending·0 cites
- 2664US11479771B2Antisense oligonucleotides for the treatment of eye diseasePROQR THERAPEUTICS II BV·Filed 2020·Granted Oct 25, 2022·0 cites·16 claims
- 2764US9605255B2Oligonucleotides for making a change in the sequence of a target RNA molecule present in a living cellPROQR THERAPEUTICS II BV·Filed 2013·Granted Mar 28, 2017·2 cites·32 claims
- 2864US2025154504A1Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemiaPROQR THERAPEUTICS II BV·Filed 2023·Application pending·0 cites
- 2963US2025304962A1Stereospecific linkages in rna editing oligonucleotidesPROQR THERAPEUTICS II BV·Filed 2025·Application pending·0 cites
- 3059US2020362348A1Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansionPROQR THERAPEUTICS II BV·Filed 2020·Application pending·0 cites
- 3157US2023323346A1Antisense oligonucleotides for rna editingPROQR THERAPEUTICS II BV·Filed 2021·Application pending·0 cites
- 3255US12180471B2Antisense oligonucleotides for the treatment of Stargardt diseasePROQR THERAPEUTICS II BV·Filed 2018·Granted Dec 31, 2024·0 cites·5 claims
- 3352US12398393B2RNA-editing oligonucleotides for the treatment of usher syndromePROQR THERAPEUTICS II BV·Filed 2020·Granted Aug 26, 2025·0 cites·15 claims
- 3452US2023235322A1Rna editing inhibitors and methods of usePROQR THERAPEUTICS II BV·Filed 2020·Application pending·0 cites
- 3552US2024141340A1Antisense oligonucleotides for use in the treatment of corneal dystrophiesPROQR THERAPEUTICS II BV·Filed 2022·Application pending·0 cites
- 3651US2022307023A1Antisense rna editing oligonucleotides comprising cytidine analogsPROQR THERAPEUTICS II BV·Filed 2020·Application pending·0 cites
- 3751US2022127609A1Antisense oligonucleotides for nucleic acid editingPROQR THERAPEUTICS II BV·Filed 2020·Application pending·0 cites
- 3851US2022340900A1Chemically modified oligonucleotides for rna editingPROQR THERAPEUTICS II BV·Filed 2020·Application pending·0 cites
- 3950US2023039928A1Antisense oligonucleotides for nucleotide deamination in the treatment of Stargardt diseasePROQR THERAPEUTICS II BV·Filed 2020·Application pending·0 cites
- 4048US2023134677A1Antisense oligonucleotides for use in the treatment of usher syndromePROQR THERAPEUTICS II BV·Filed 2021·Application pending·0 cites
- 4146US10370660B2Antisense oligonucleotides to treat Dystrophic Epidermolysis BullosaPROQR THERAPEUTICS II BV·Filed 2016·Granted Aug 6, 2019·0 cites·20 claims
- 4246US2021079393A1Antisense oligonucleotides for rna editingPROQR THERAPEUTICS II BV·Filed 2019·Application pending·0 cites
- 4345US2022177894A1Antisense oligonucleotides for immunotherapyPROQR THERAPEUTICS II BV·Filed 2020·Application pending·0 cites
- 4444US2022213478A1Antisense oligonucleotides for the treatment of usher syndromePROQR THERAPEUTICS II BV·Filed 2020·Application pending·0 cites
- 4542US2022265695A1Opthalmic compositions comprising viscosifying polymers and nucleic acidsPROQR THERAPEUTICS II BV·Filed 2020·Application pending·0 cites
- 4640US2022098584A1Antisense oligonucleotides for the treatment of leber`s congenital amaurosisPROQR THERAPEUTICS II BV·Filed 2020·Application pending·0 cites
- 4721US2017327821A1Oligonucleotides for genomic dna editingPROQR THERAPEUTICS II BV·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when PROQR THERAPEUTICS II BV files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →